Treatment with SVF significantly decreased expression of LYVE-1, Prox1, PDPN, and VEGF-R3 comparing with the control AD model (p < 0.05, p < 0.01, p < 0.001, p < 0.001). Here, LYVE1 is linked to Alzheimer disease.